NASDAQ:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free MDNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.16▼$0.3952-Week Range N/AVolume1.27 million shsAverage Volume160,047 shsMarket Capitalization$10.93 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipSocial Media Get Medicenna Therapeutics alerts: Email Address Medicenna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$2.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.17) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.72 out of 5 starsMedical Sector832nd out of 909 stocksPharmaceutical Preparations Industry392nd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicenna Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MDNA. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDNA. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.38% of the stock of Medicenna Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Medicenna Therapeutics Stock (NASDAQ:MDNA)Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 MDNA Stock News HeadlinesApril 24, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual MeetingApril 11, 2024 | investing.comMedicenna reports advancement in cancer immunotherapyApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 4, 2024 | finance.yahoo.comMedicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 1, 2024 | morningstar.comMedicenna Therapeutics Corp MDNAFebruary 14, 2024 | finance.yahoo.comMedicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateJanuary 12, 2024 | tmcnet.comMedicenna Announces Appointment of New AuditorDecember 19, 2023 | finance.yahoo.comMedicenna Announces Trading on the OTCQB Under the Symbol MDNAFApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinNovember 20, 2023 | finance.yahoo.comMDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…November 14, 2023 | finance.yahoo.comMedicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 13, 2023 | finance.yahoo.comMDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11November 6, 2023 | finance.yahoo.comMedicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)November 3, 2023 | finance.yahoo.comMedicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 30, 2023 | msn.comWhy Is Medicenna Therapeutics (MDNA) Stock Down Today?October 27, 2023 | finance.yahoo.comMedicenna Announces Nasdaq Delisting and Cutback of Management TeamOctober 25, 2023 | finance.yahoo.comMedicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsOctober 13, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)October 10, 2023 | markets.businessinsider.comMedicenna Therapeutics Names Humphrey Gardner CMOOctober 10, 2023 | finance.yahoo.comMedicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerSeptember 28, 2023 | finance.yahoo.comMedicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 13, 2023 | nasdaq.comMedicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94August 22, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)August 15, 2023 | msn.comMDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…August 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Medicenna TherapeuticsAugust 14, 2023 | finance.yahoo.comMedicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters ManagementAugust 8, 2023 | benzinga.comMedicenna Therapeutics's Earnings: A PreviewSee More Headlines Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/24/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MDNA CUSIPN/A CIK1807983 Webwww.medicenna.com Phone(416) 648-5555Fax416-572-7501Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$3.00 Low Stock Price Target$2.50 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.68% Return on Assets-35.17% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / BookN/AMiscellaneous Outstanding Shares69,637,000Free Float46,587,000Market Cap$10.93 million OptionableNot Optionable Beta1.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Fahar Merchant Ph.D. (Age 66)Founder, Chairman, President & CEO Comp: $327.41kMs. Rosemina Merchant B.Sc. (Age 66)M.E.Sc, Founder & Chief Development Officer Comp: $262.62kMr. Jeff Caravella M.B.A.Chief Financial OfficerMr. Brent Meadows M.B.A.Chief Business OfficerDr. Humphrey A. R. Gardner FCAPM.D., Chief Medical OfficerDr. Samuel R. Denmeade M.D.Scientific AdvisorMore ExecutivesKey CompetitorsEterna TherapeuticsNASDAQ:ERNAGalera TherapeuticsNASDAQ:GRTXMonopar TherapeuticsNASDAQ:MNPRGuardion Health SciencesNASDAQ:GHSIMoleculin BiotechNASDAQ:MBRXView All Competitors MDNA Stock Analysis - Frequently Asked Questions Should I buy or sell Medicenna Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares. View MDNA analyst ratings or view top-rated stocks. What is Medicenna Therapeutics' stock price target for 2024? 2 analysts have issued 1 year price objectives for Medicenna Therapeutics' stock. Their MDNA share price targets range from $2.50 to $3.00. On average, they predict the company's share price to reach $2.75 in the next year. View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts. How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (NASDAQ:MDNA) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. During the same period in the previous year, the firm earned ($0.06) earnings per share. This page (NASDAQ:MDNA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
